Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Equity Ratio (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Equity Ratio for 16 consecutive years, with 0.52 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 23.67% to 0.52 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.52, a 23.67% decrease, with the full-year FY2025 number at 0.52, down 23.67% from a year prior.
  • Equity Ratio was 0.52 for Q4 2025 at Myriad Genetics, up from 0.51 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.78 in Q2 2022 to a low of 0.51 in Q3 2025.
  • A 5-year average of 0.67 and a median of 0.68 in 2023 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: rose 18.01% in 2021, then dropped 24.33% in 2025.
  • Myriad Genetics' Equity Ratio stood at 0.73 in 2021, then rose by 0.84% to 0.74 in 2022, then decreased by 7.56% to 0.68 in 2023, then decreased by 0.12% to 0.68 in 2024, then fell by 23.67% to 0.52 in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Equity Ratio are 0.52 (Q4 2025), 0.51 (Q3 2025), and 0.57 (Q2 2025).